Provided by Tiger Trade Technology Pte. Ltd.

Solid Biosciences

6.18
+0.31005.28%
Post-market: 6.290.1100+1.78%17:25 EST
Volume:922.30K
Turnover:5.68M
Market Cap:481.49M
PE:-2.49
High:6.32
Open:5.91
Low:5.91
Close:5.87
52wk High:7.37
52wk Low:2.41
Shares:77.91M
Float Shares:37.61M
Volume Ratio:0.70
T/O Rate:2.45%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4800
EPS(LYR):-3.0550
ROE:-86.83%
ROA:-43.67%
PB:2.21
PE(LYR):-2.02

Loading ...

FDA Grants Orphan Drug Designation to Solid Biosciences' SGT-212 for Friedreich’s Ataxia

Reuters
·
Jan 13

Solid Biosciences Receives FDA Orphan Drug Designation for Sgt-212 Dual-Route Gene Therapy for the Treatment of Friedreich’s Ataxia

THOMSON REUTERS
·
Jan 13

Solid Biosciences- Dosing of First Participant in Phase 1B Falcon Trial Completed, Initial Data Expected in H2 2026

THOMSON REUTERS
·
Jan 13

Solid Biosciences doses first participant in Phase 1b FALCON trial on SGT-212

TIPRANKS
·
Jan 12

Solid Biosciences Doses First Participant in Phase 1b Trial of SGT-212 Gene Therapy for Friedreich’s Ataxia

Reuters
·
Jan 12

Solid Biosciences Inc: Expect to Share an Initial Data Update in Second Half of 2026

THOMSON REUTERS
·
Jan 12

Solid Biosciences Doses First Participant in First-in-Class Phase 1B Falcon Trial Evaluating Sgt-212 Dual-Route Gene Therapy for the Treatment of Friedreich’s Ataxia

THOMSON REUTERS
·
Jan 12

Solid Biosciences Grants 7,000 RSUs to New Employee Under Inducement Plan

Reuters
·
Jan 06

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jan 06

Solid Biosciences Announces Duchenne Muscular Dystrophy Added to National Recommended Uniform Screening Panel by the U.S. Department of Health and Human Services

GlobeNewswire
·
Dec 17, 2025

BRIEF-Solid Biosciences To Showcase Proprietary Next-Generation Capsid AAV-SLB101 And Cardiac Gene Therapy Pipeline At The 22nd Global Cardiovascular Clinical Trialists Forum

Reuters
·
Dec 08, 2025

Solid Biosciences to Showcase Proprietary Next-Generation Capsid Aav-Slb101 and Cardiac Gene Therapy Pipeline at the 22Nd Global Cardiovascular Clinical Trialists (Cvct) Forum

THOMSON REUTERS
·
Dec 08, 2025

Solid Biosciences: Better Positioned To Compete In DMD Gene Therapy, Says Bullish Analyst

Benzinga_recent_news
·
Dec 05, 2025

Needham & Co Initiates Coverage on Solid Biosciences With Buy Rating, $16 Price Target

MT Newswires Live
·
Dec 04, 2025

Solid Biosciences Initiated at Buy by Needham

Dow Jones
·
Dec 04, 2025

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Dec 02, 2025

Solid Biosciences Receives FDA Rare Pediatric Disease Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia

GlobeNewswire
·
Dec 01, 2025

Solid Biosciences management to meet with Citizens JMP

TIPRANKS
·
Nov 25, 2025

Solid Biosciences Grants Non-Exclusive AAV-SLB101 License to Andelyn Biosciences

Reuters
·
Nov 17, 2025

Solid Biosciences Inc - Aav-Slb101 Well Tolerated in 23 Participants in Clinical Trial

THOMSON REUTERS
·
Nov 17, 2025